Sanofi and Regeneron’s appeal to suspend Amgen injunction denied
12-01-2017
Amgen wins injunction in Sanofi Repatha suit
06-01-2017
Amgen secures patent win in Repatha case
04-01-2017
Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent (alirocumab).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Sanofi, Regeneron Pharmaceuticals, patent, patent infringement, evolocumab, Repatha, Praluent, injunction, appeal
